The NANBIOSIS ICTS is organised into five platforms: 1) production of biomolecules, 2) production of biomaterials and nanomaterials, 3) preclinical validation: characterisation of tissues, biomaterials and surfaces, 4) preclinical validation: bioimaging, and 5) high-performance computing, comprising 27 complementary and coordinated units, located in different centres in Andalusia, Aragon, Catalonia, Extremadura, Madrid and the Basque Country.
NANBIOSIS employs a one-stop-shop system to provide tailor-made comprehensive solutions to the challenges encountered by researchers in nanomedicine, medical diagnostics and tissue engineering and regenerative medicine devices, including the design and production of bio-nanomaterials and their nanoconjugates, and the characterisation of these and medical tissues and devices, from a physicochemical, functional, toxicological and biological perspective through to preclinical in vivo validation.
NANBIOSIS offers solutions in multiple fields of application, and its configuration supports multidisciplinary cutting-edge studies. It is a distributed ICTS with three nodes:
The Centre for Biomedical Research Network (CIBER) is a consortium attached to the Carlos III Health Institute created in 2006 and organised into eleven research areas. The CIBER-BBN area is currently made up of 46 research groups selected from all over Spain for their scientific excellence. Its aim is to conduct translational research in bioengineering, biomaterials and nanomedicine and communicate the results to industry.
The Jesús Usón Minimally Invasive Surgery Centre (CCMIJU) is a public research centre focused on contributing to the increase of knowledge and use of technologies related to biomedicine and minimally invasive surgery. The centre is located in Cáceres, Spain.
BIONAND is a centre operated jointly by the Regional Government of Andalusia and the University of Malaga, established as a space for research excellence in nanomedicine to generate new systems for the diagnosis, prevention and treatment of diseases through the creation and development of devices, materials and approaches on a nanometric scale.